Navigation Links
HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference
Date:7/28/2008

RESEARCH TRIANGLE PARK, N.C., July 27 /PRNewswire/ -- Timothy Mastro, MD, FACP, DTM&H, who joins Family Health International (FHI) on August 1st as Senior Director of Research, will share information on promising research into pre-exposure prophylaxis (PrEP) for HIV prevention at the International AIDS Conference in Mexico City.

Dr. Mastro's presentation, titled "Pre-Exposure Prophylaxis: Current and Planned Trials," will examine ongoing and upcoming clinical trials that suggest oral doses of certain antiretroviral therapies taken daily may prove effective in protecting people from HIV infection. The successful development of PrEP would be especially useful to women and others who may not be empowered to negotiate consistent condom use with their sexual partners.

Dr. Mastro, who joins FHI from the Centers for Disease Control and Prevention (CDC), is one of the leading experts on HIV/AIDS prevention. During his tenure at the CDC, Dr. Mastro oversaw HIV prevention research activities, including a landmark study on mother-to-child HIV transmission, trials of microbicides for women, and the first international HIV vaccine efficacy trial. He has also served as chief of the CDC HIV Vaccine Section and directed CDC's participation in the President's Emergency Plan for AIDS Relief (PEPFAR). At FHI, Dr. Mastro will support the organization's commitment to continue to expand its global leadership role in public health and development, particularly in HIV/AIDS prevention and treatment research and programs.

WHAT: FHI's Dr. Timothy Mastro Presents on "Pre-Exposure Prophylaxis:

Current and Planned Trials"

WHERE: XVII International AIDS Conference

Centro Banamex, Mexico City Session Room 9

WHEN: Thursday, August 7, 2008

2:30-4:00 p.m.

Dr. Mastro's presentation is part of a symposium titled "The Future of Microbicides: from Vaginal ART to PREP," which will examine the road forward for research on female-controlled HIV prevention methods in the face of negative results from some recent clinical trials. Other presentations at the session will include "Future Promising Microbicidal Products: What to Learn from the In Vitro Work," "ART-Containing Vaginal Microbicides in the Clinical Pipeline: A Status of the Studies," and "The Use of Oral and Topical PREP at Population Level: What Are the Issues?"

Other notable FHI presentations at the International AIDS Conference include:

"Meeting the Sexual and Reproductive Health Needs of People Living with HIV: Critical to Human Rights and Prevention" by Ms. Rose Wilcher

Sunday, August 3, 2008

3:45-5:45 p.m. in Skills Building Room 5

"Vaccines and Microbicides: Where Do We Go From Here?" by Dr. Lut Van Damme
Monday, August 4, 2008

11:00 a.m.-1:00 p.m. in Session Room 1

Family Health International

Family Health International (FHI) has been at the forefront of international public health initiatives since 1971. With a staff of 2,200 working in more than 65 countries, FHI leads and supports research and programs that address the most pressing public health needs of the developing world - HIV/AIDS prevention, care, and treatment; reproductive health; malaria; tuberculosis; and avian influenza as well as other chronic and infectious diseases. FHI's work is made possible by close relationships with funding partners, host-country governments, non-governmental organizations, research institutions and universities, community and faith-based groups, and private-sector organizations.

Contact: Tae Crotty

Director of Communications

1-571-225-5819

tcrotty@fhi.org


'/>"/>
SOURCE Family Health International
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
2. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
3. U.S. Prevention Medicine: Employers Can Help Workers Avoid Heart Attacks
4. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
5. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
7. Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool
8. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
9. New York Infection Prevention Expert Named Recipient of Carole DeMille Award
10. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
11. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and ... this old family recipe, which is meant to relieve gout and pain caused by ... a 12-hour energy boost every time. It relieved what VA doctors called the worst ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... proudly announced today that a new solution for Emergency Departments (ED) has been ... tight space in Emergency Department examination rooms, and with a simplified pallet of ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
Breaking Medicine News(10 mins):